Stellar trial statin. 4 HMG CoA inhibitors .

Stellar trial statin MERCURY II was a 16-week, randomized, open-label, 2-period, parallel-group, multicenter study. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. 8 mmol/L, Jones PH, et al. Jul 15, 2003 · This multicenter trial, which is the largest trial of its kind to date comparing the lipid-modifying efficacy of statins, showed the greater efficacy of rosuvastatin in reducing LDL cholesterol, compared with atorvastatin, simvastatin, and pravastatin across dose ranges. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of high-intensity statins are generally used as the first-line therapy in patients with CAD. [Google Scholar] 19. This means that those at increased risk of cardiovascular complications due to high cholesterol now have access to a fourth funded HMG-CoA reductase inhibitor, or statin. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). statin treatment including the potential risk of new-onset DM or worsening of DM. Across dose ranges, rosuvastatin reduced total cholesterol significantly more than all comparators and triglycerides significantly more (p <0. Methods: As part of the STELLAR trial, 1,146 women with elevated low-density lipoprotein cholesterol (LDL-C DOI: 10. Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors that are effective in the reduction of total and LDL cholesterol. The results revealed that the efficacy of rosuvastatin 40 mg had the best efficacy with 55. In Intensive Statin Regimens and Coronary Disease n engl j med 365;22 nejm. , 2006; Welty et al. In view of the evidence, statins should be seriously considered in people with diabetes at least by age 50 in men and 60 in women. This helps to eliminate bias and obtain accurate data on the efficacy and safety of Rosuvastatin. 2003;92:152-160. 8% to 9. 8% statin treated vs 4. Interventions Participants were assigned to receive either Moreover, patients on rosuvastatin had significant increments in high-density lipoprotein (HDL) cholesterol compared to other statins . Design Randomised, open label, multicentre trial. Am J Cardiol. Rosuvastatin gives greatest reduction in LDL at all doses as compared to other statins. Methods A total of 996 patients with hypercholesterolemia (LDL-C ≥ 3. HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A) reduktazės inhibitoriai (slopintojai) – vaistų, vartojamų cholesterolio kiekiui kraujo plazmoje sumažinti, klasė. 125,126 With respect to breast cancer, some studies have found no association between statin use and breast cancer mortality,127 while others suggest that the STELLAR (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin) study, compared rosuvastatin, atorvastatin, simvastatin and pravastatin across licensed doses for reducing LDL cholesterol and other lipid parameters in patients (n=2,431) with hypercholesterolaemia (LDL-C > 160 and < 250 mg/dL [> 4. However, statin adherence in actual practice tends to be suboptimal, leading to Mar 5, 2010 · After including more head-to-head trials and summarizing them with systematic review and meta-analysis, we found the therapeutic equivalent doses of statins were similar to that of the CURVES and STELLAR trials. Conclusion In summary, 10 mg of rosuvastatin tablet was comparable to 10 mg of atorvastatin tablet and more efficacious than 10 mg tablet simvastatin in reducing LDL levels after 12 FIGURE 2. FIGURE 2 . Slightly raises HDL cholesterol: HDL is the “good” type of cholesterol. Methods: As part of the STELLAR trial, 1,146 women with elevated low-density lipoprotein cholesterol (LDL-C Design: A retrospective pharmacoeconomic analysis was performed using data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial. 1 All participants were followed prospectively for the primary trial end point of first-ever myocardial infarction, stroke Adapted from the STELLAR trial, . Oct 18, 2023 · Objective To compare the long term efficacy and safety of rosuvastatin with atorvastatin treatment in adults with coronary artery disease. 09. 2004;110:227-239. The lower the better. Our results are also consistent with two earlier systematic reviews by the VHA and the OHRC . doi: 10. An individual patient data pooled analysis was performed of 32,258 patients in studies comparing the efficacy of Sep 1, 2004 · The goal of this study was to examine prospectively the effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin across dose ranges on non-HDL-C, apo B, apo A-I, and total cholesterol Nov 29, 2007 · Patients with systolic heart failure have generally been excluded from statin trials. Likewise, rosuvastatin increased HDL STELLAR Trial. org november 20, 2008 C urrent treatment algorithms for the prevention of myocardial infarction, stroke, and death from Despite the established efficacy of statins, the number of patients on statin monotherapy who achieve and maintain LDL-C levels recommended by current guidelines is suboptimal. The reason is simple: ezetimibe by further depleting hepatic cholesterol pools upregulates additional LDLr beyond those induced by the statins. Of all the 1926 participants with hypercholesterolemia, 994 (51. 1–4 In a previous trial, atorvastatin was compared across its dose range with other statins (simvastatin, prava-statin, lovastatin, and fluvastatin), but patient numbers were small (10 to 73 per group) and pairwise compar- Sep 1, 2004 · CLINICAL THERAPEUTICSVoL. 6%) participants received the combination therapy with ezetimibe and statin and 932(48. 4%) received double-dose statin therapy alone. 2003; 92(2):152–60. Jan 1, 2016 · Despite guidelines recommending the use of statin treatment in hypercholesterolemic women, this patient group is often undertreated. Although dose-dependent reductions in levels of atherogenic lipids are observed with all statins, the impact of increasing dose has not been fully elucidated. Secondary objectives included comparing rosuvastatin with comparators for other lipid modifications and achievement of National Cholesterol Nov 5, 2015 · The STELLAR trial and the PULSAR study demonstrated a remarkable reduction in LDL, total cholesterol, and triglycerides compared to other statins (Clearfield et al. 2 mg/L) and LDL cholesterol levels <130 mg/dL (median, 108 mg/dL) to either rosuvastatin 20 mg or to placebo. Participant Selection Dec 28, 2022 · Moreover, patients on rosuvastatin had significant increments in high-density lipoprotein (HDL) cholesterol compared to other statins (Table 1). established results based on the dose-to-dose comparisons between atorvastatin and rosuvastatin efficacy in reducing LDL-C . ^ Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group Adapted from the MERCURY II trial. 19 This subgroup analysis examines the Jan 1, 2010 · Statins are the most commonly prescribed agents for lowering levels of low-density lipoprotein (LDL) cholesterol. 47 mmol/L respectively]; triglycerides < 400 mg/dL [< 4. 1 This was a 6-week, parallel-group, open-la- tein (LDL) cholesterol and achieving LDL cholesterol goals than atorvastatin, simvastatin, or pravastatin. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). Clinical trials have showed that rosuvastatin is an effective cholesterol-lowering medication, but it is also important to assess its cost-effectiveness. METHODS: The cost-effectiveness of cholesterol-lowering therapy with rosuvastatin compared to atorvastatin, simvastatin, and pravastatin was estimated with a Markov model of cardiovascular The goal of this study was to examine prospectively the effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin across dose ranges on non-HDL-C, apo B, apo A-I, and total cholesterol (TC):HDL-C, low-density lipoprotein cholesterol (LDL-C):HDL-C, non-HDL-C:HDL-C, and apo B:apo A-I ratios in patients with hypercholesterolemia (LDL-C >-160 mg/dL and <250 mg/dL and triglycerides <400 Jones PH, Davidson MH, Stein EA, et al. Nov 15, 2021 · Rosuvastatin is fully funded in New Zealand from 1 December 2021, subject to Special Authority criteria. Bays H. The STELLAR study (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin) is a six-week, randomized, open-label study comparing the efficacy, as an adjunct to diet, of Grundy SM, Cleeman JI, Merz CNB, et al; for the Coordinating Committee of the National Cholesterol Education Program. Mar 19, 2008 · These results are consistent with the STELLAR trial where rosuvastatin, atorvastatin, and simvastatin reduced LDL levels by 45. 1–4 In a previous trial, atorvastatin was compared across its dose range with other statins (simvastatin, prava-statin, lovastatin, andfluvastatin), but patient numbers were small (10 to 73 per group) and pairwise compar- 䊚2003 by Excerpta Medica, Inc. Miller PS, Smith DG, Jones P. Am J Cardiol; 2005 Jun 01; 95(11):1314-9. ⚫ Physicians make decisions for not only statin intensity but also statin type. 8, and 28. Jones, MD,1 Donald B. 8. The efficacy and safety data from the entire clinical programme show a In statin therapies for elevated lipid levels compared across doses to rosuvastatin (STELLAR trial), Jones et al. May 15, 2009 · The once-a-week dosing schedule was well tolerated in this small group of patients with a history of adverse events to 1 or more statin drugs and led to significantly improved lipoprotein levels, but large randomized trials are needed to confirm these findings and determine whether the once-a-week alternative dosing schedule is more desirable Nov 27, 2009 · The JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) sought to investigate whether statin therapy would reduce first cardiovascular events in individuals who have low levels of LDL-C (outside of current treatment guidelines for statin therapy), but are nonetheless at increased Selection of studies. STELLAR Trial. Type 2 diabetic patients (T2D) have an increased risk of atherosclerotic cardiovascular diseases (ASCVD), 1 and statin therapy had been shown to reduce ASCVD events as compared with placebo in T2D. 1–4 In a previous trial, atorvastatin was compared across its dose range with other statins (simvastatin, prava-statin, lovastatin, and fluvastatin), but patient numbers were small (10 to 73 per group) and pairwise compar- Rosuvastatin has the longest terminal half-life of the statins and is only minimally metabolized by the cytochrome P450 (CYP 450) enzyme system with no significant involvement of the 3A4 enzyme and the absence of clinically significant drug interactions between rosuvastatin and other drugs known to inhibit CYP 450 enzymes. Methods: As part of the STELLAR trial, 1,146 women with elevated low-density lipoprotein cholesterol (LDL-C Grundy SM, Cleeman JI, Merz CNB, et al; for the Coordinating Committee of the National Cholesterol Education Program. Table 1 Baseline characteristics of patients with previous statin intolerance (n 50) Men 19 (38%) Women 31 (62%) Age (yrs) (mean Jul 1, 2022 · The guidelines recommendations are based on landmark trials and a large meta-analysis of the statin landmark trials, such as Intensive vs Moderate Lipid Lowering with Statins after Acute Coronary Syndromes (PROVE IT) trial, Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease (TNT) trial, Incremental Decrease through Aggressive Lipid Lowering (IDEAL) trial, and a undertreated. The cost-effectiveness of rosuvastatin 10-40 mg was compared with atorvastatin 10-80 mg, pravastatin 10-40 mg and both branded and generic simvastatin 10-80 mg in Aug 1, 2003 · In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor) was compared with that of atorvastatin To perform these virtual clinical trials, the core Archimedes model was expanded to include data on rosuvastatin 20 mg/d and 40 mg/d doses from the JUPITER and STELLAR trials, and data on atorvastatin 40 mg/d and 80 mg/d from the CARDS, ASCOT-LLA, STELLAR, and TNT trials. 8 A meta-analysis of 164 short studies confirmed the STELLAR findings. In fact it is noted that across dose ranges, the HDL cholesterol increasing effect of rosuvastatin was consistent across the dose range and was significantly higher (P < 0. Least-squares mean (SE) percentage changes from baseline in LDL cholesterol at week 6, and mean differences (SE) across the dose ranges from the analysis of covariance (versus atorvastatin and pravastatin) and analysis of variance (versus simvastatin) for (A) rosuvastatin versus atorvastatin (95% confidence interval 6. gov identifier: NCT00654537) compared rosuvastatin treatment with three other widely used statins (atorvastatin, simvastatin, and pravastatin) in a hypercholesterolemic patient population. 15, 16 Detailed intensity classifications of the various types of statin are presented in Supplemental Table 1. 0). Jan 1, 2003 · In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor) was compared with that of atorvastatin CONCLUDE Statin trials in primary prevention, starting with the landmark WOSCOPS trial, have found substantial relative reductions in cardiovascular events without an increase in noncardiovascular mortality. Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. Jun 1, 2005 · In a 6-week, parallel-group, open-label, multicenter, randomized trial (Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin [STELLAR]), the effects of rosuvastatin (10, 20, or 40 mg) on low-density lipoprotein (LDL) cholesterol levels were compared with those of atorvastatin (10, 20, 40, or 80 mg), pravastatin (10, 20, or 40 mg), and simvastatin (10, 20, 40, or 80 The Stellar Study utilizes a rigorous research design to ensure reliable results. The higher the better. 22 This was a 6-week open-label, parallel group, multicenter trial involving 2,431 adults with hypercholesterolemia randomized to rosuvastatin 10, 20, and 40 mg, atorvastatin 10, 20, 40, and 80 mg, pravastatin 10, 20, and 40 mg or In patients with hypercholesterolaemia, rosuvastatin is a cost-effective statin option in treating to LDL-C goals and Sensitivity analyses showed that the results were robust to variations in both statln efficacy and price. 15 The efficacy of different statins in a dose-dependent manner on lowering LDL cholesterol has been evaluated. 7,8 In the Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial, rosuvastatin 10mg, atorvastatin 20mg, simvastatin 20mg and BackgroundRosuvastatin calcium (CRESTOR®) has demonstrated superior efficacy in reducing low-density lipoprotein cholesterol (LDL-C). (STELLAR Trial). Statin safety: an overview and assessment of the data–2005. 19 This subgroup analysis examines the This drive towards generic prescribing for statins for all patients, with reduced efficacy, is against the published data from a large series of randomised-controlled trials and is counterintuitive. Also Dec 29, 2024 · Identify the landmark trials that continue to support the benefits of aggressive therapy with statins to reduce lipid levels to, or below, The Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (ATP III) guidelines for both primary and secondary cholesterol levels ≥1. 2, 3 Therefore, 6 weeks was considered an adequate time to show the relative LDL tein (LDL) cholesterol and achieving LDL cholesterol goals than atorvastatin, simvastatin, or pravastatin. Until recently, secondary preventive management utilizing a statin required merely the selection of the drug and ensuring that the patient would take the drug for the rest of their life. the STELLAR (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin) study, compared rosuvastatin, atorvastatin, simvastatin and pravastatin across licensed doses for reducing LDL cholesterol and other lipid parameters in patients (n=2,431) with hypercholesterolaemia (LDL-C > 160 and < 250 mg/dL [> 4. org december 1, 2011 2079 R andomized clinical trials have consistently shown that inhibitors of For example, the STELLAR trial found rosuvastatin (40 mg) to be the most effective on increasing HDL-C. Characteristics of the 11 eligible studies are listed in Table 1. (Am J Cardiol 2003;92:152–160) t usual starting doses, rosuvastatin is more effiA cacious in reducing plasma low-density lipoprotein (LDL) cholesterol and achieving LDL cholesterol 6-week trial was to compare the LDL cholesterol reducing efficacy of the dose range of rosuvastatin with that of the Food and Drug Jun 1, 2005 · In a 6-week, parallel-group, open-label, multicenter, randomized trial (Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin [STELLAR]), the effects of rosuvastatin (10, 20, or 40 mg) on low-density lipoprotein (LDL) cholesterol levels were compared with those of atorvastatin (10, 20, 40, or 80 mg), pravastatin (10, 20, or 40 mg), and simvastatin (10, 20, 40, or 80 Jun 1, 2005 · Clinical data were obtained from the Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial. 7%), (B) rosuvastatin versus simvastatin, and (C Statinai, HMG-KoA (angl. 18 Aug, 10. The meta-analysis showed Jul 15, 2003 · The 6-week study period was shorter than in most previous studies of statin efficacy 2, 3, 5, 18; however, it is well established that statins exhibit most of their LDL cholesterol reducing effects within 2 weeks and produce full effects by 4 to 6 weeks. METHODS Effectiveness: Clinical data were provided by the STELLAR trial, which is described in detail else-where. 22 – 24, 27, 41 The effect of statins on clinical outcomes is modeled Jul 1, 2003 · The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol. 0 mmol/L or 40 mg/dL reduction of plasma LDL-cholesterol (LDL-C) reducing the annual Jan 1, 2018 · the STELLAR (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin) study, compared rosuvastatin, atorvastatin, simvastatin and pravastatin across licensed doses for reducing LDL cholesterol and other lipid parameters in patients (n=2,431) with hypercholesterolaemia (LDL-C > 160 and < 250 mg/dL [> 4. This subgroup analysis of the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial examines the effects of statin therapy in hypercholesterolemic women. Hunninghake, MD,2. use of statin therapy. In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor*) was compared with that of atorvastatin (Lipitor†), simvastatin (Zocor‡), and pravastatin (Pravachol§) for lowering plasma low-density lipoprotein cholesterol (LDL-C) after 6 weeks of Cain VA, Blasetto JW for the STELLAR Study Group. DESIGN A retrospective pharmacoeconomic analysis was performed using data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial. 9 years (maximum, 5. 8 mmol/L, maintenance of the same intensity without titration for those whose LDL cholesterol levels were ≥1. Jul 15, 2003 · The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol. Results favoring rosuvastatin versus the comparators were also reported for patients: who had triglycerides 200 mg/dl ( 2. 001) than simvastsatin and pravastatin. Thus far, reports from phase II/III clinical trials indicate that statin use does not improve progression-free survival of patients who have been diagnosed with metastatic colorectal tumors. May 1, 2009 · To address this public health issue, the JUPITER investigators randomly allocated 11 001 men and 6801 women who had hsCRP levels >2 mg/L (median, 4. Apr 8, 2004 · Several large, randomized, controlled trials have documented that cholesterol-lowering therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduces the risk of death undertreated. Inclisiran helps to lower bad (LDL) cholesterol. 1016/S0002-9149(03)00530-7) Least-squares mean (SE) percentage changes from baseline in LDL cholesterol at week 6, and mean differences (SE) across the dose ranges from the analysis of covariance (versus atorvastatin and pravastatin) and analysis of variance (versus simvastatin) for (A) Dec 21, 2006 · Background Many patients at high risk of cardiovascular disease do not achieve recommended low-density lipoprotein cholesterol (LDL-C) goals. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). 0% LDL-C ^ Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group. 8, 36. Conclusions: Statin therapies in the STELLAR trial led to reductions in LDL-C, non-HDL-C, and triglycerides and increases in HDL-C among hypercholesterolemic women, with rosuvastatin providing the greatest reductions in LDL-C and non-HDL-C. Jan 15, 2016 · The Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial (clinicaltrials. O'donnell , and Peter Jones View all authors and affiliations Mar 6, 2023 · In the STELLAR trial, the addition of 24-week treatment with sotatercept to background therapy with currently available medications improved exercise capacity as assessed by 6-minute walk distance Jan 15, 2016 · The Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial (clinicaltrials. Specifically, rosuvastatin 10 mg lowered LDL-C more than atorvastatin Jan 1, 2003 · In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor) was compared with that of atorvastatin (Lipitor), simvastatin (Zocor), and pravastatin (Pravachol) for lowering plasma low-density lipoprotein cholesterol (LDL-C) after 6 weeks of treatment. 2004. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) Am J Cardiol. STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. Nov 11, 2003 · Completed randomized trials of statin therapy demonstrate that 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors reduce the risk of myocardial infarction, stroke, and other cardiovascular events among individuals with established coronary disease and overt hyperlipidemia. To illustrate the sensitivity of this study’s findings to the assumptions about pleiotropic effects, we explored two additional cases, varying the CHD-specific pleiotropic benefit of each statin while Jan 1, 2018 · the STELLAR (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin) study, compared rosuvastatin, atorvastatin, simvastatin and pravastatin across licensed doses for reducing LDL cholesterol and other lipid parameters in patients (n=2,431) with hypercholesterolaemia (LDL-C > 160 and < 250 mg/dL [> 4. A meta-anlaysis performed by the Cholesterol Treatment Trialists’ (CTT) Collaborators in 2005 evaluated over 90,000 participants in 14 statin trials and demonstrated no significant differences in the rates of death from non-vascular causes in statin treatment groups compared with placebo (3. American Journal of Cardiology 2003 92152-160DOI: (10. Least-squares mean (SE) percentage changes from baseline in HDL cholesterol at week 6 across dose ranges, and mean differences (SE) from analysis of variance (versus atorvastatin) or covariance (versus simvastatin and pravastatin) for (A) rosuvastatin versus atorvastatin for equivalent doses (the difference across the dose range for the rosuvastatin vs atorvastatin comparison could 7. Am J Cardiol 2003;92:152-160 Sep 22, 2008 · In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor) was compared with that of atorvastatin (Lipitor ), simvastatin (Zocor), and pravastatin (Pravachol) for lowering plasma low-density lipoprotein cholesterol (LDL-C) after 6 weeks of treatment. 3 A number of large randomized control trials have demonstrated unequivocally that lowering LDL-C particularly with statins reduces the risk of cardiovascular deaths and events. , 2016 Mar 1, 2005 · Download Citation | Cost-Efficacy Analysis of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Based on Results of the STELLAR Trial: Clinical Implications for Therapeutic Selection | To CRESTOR is indicated to reduce the risk of myocardial infarction, stroke and arterial revascularization procedures in patients without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men ≥50 and women ≥60), high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CVD risk factor, such as Clinical trials have demonstrated that either initiating or up-titrating a statin dose substantially reduce Low-Density Lipoprotein-Cholesterol (LDL-C) levels. Participants 4400 adults (age ≥19 years) with coronary artery disease. Cost effectiveness was assessed with the net monetary benefit approach and a 1-year time horizon. 14 and < 6. prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins undertreated. 2003;92:152–160. Te present study also revealed that as the doses of rosuvastatin, simvastatin, and pravastatin increased, HDL-C also increased, with rosuvastatin having the greatest effect. statin 10 to 80 mg; the European LDL cholesterol goal o f < 3. Recently, the LODESTAR trial (low-density lipoprotein cholesterol- Lastly in the ENHANCE trial and other statin/ezetimibe trials there was significantly more TG-lowering when ezetimibe (Zetia) was added to a statin than statin monotherapy. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. 1016/s0002-9149(03)00530-7. A randomized controlled trial design is employed, where participants are randomly assigned to either the Rosuvastatin group or the control group. However, healthcare providers and authorities require informati undertreated. Lastly in the ENHANCE trial and other statin/ezetimibe trials there was significantly more TG-lowering when ezetimibe (Zetia) was added to a statin than statin monotherapy. 1016/J. ^ Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group Jul 15, 2003 · The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol. Statin therapies in the STELLAR trial led to reductions in LDL-C, non-HDL-C, and triglycerides and increases in HDL-C among hypercholesterolemic women, with rosuvastatin providing the greatest reductions in LDL-C and non-HDL-C. 26, No. Oct 10, 2022 · Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept, an investigational activin Jul 28, 2024 · the STELLAR (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin) study, compared rosuvastatin, atorvastatin, simvastatin and pravastatin across licensed doses for reducing LDL cholesterol and other lipid parameters in patients (n=2,431) with hypercholesterolaemia (LDL-C > 160 and < 250 mg/dL [> 4. 2, 3 A meta-analysis of statin trials has shown that each 1. A Dec 4, 2013 · STELLAR was reported to be the most comprehensive trial on the effectiveness of the widely used statins to date. Background Rosuvastatin calcium (CRESTORQ{J) has demonstrated superior efficacy in reducing low-density lipoprotein cholesterol (LDL-C). ⚫ However, few RCTs have directly compared the long-term clinical outcomes of the two most potent statins (rosuvastatin versus atorvastatin) in patients with CAD. 7 mmol/L [130 and Study objective: To compare the cost/1% reduction in low-density lipoprotein cholesterol (LDL) and the cost/patient achieving the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL goal based on the results of the Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial. In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor) was compared with that of atorvastatin (Lipitor), simvastatin (Zocor), and pravastatin (Pravachol) for lowering plasma low-density lipoprotein cholesterol (LDL-C) after 6 weeks of treatment. . 4 and < 5. Oct 1, 2009 · The Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin (STELLAR) trial findings also support that rosuvastatin is more efficacious than milligram-equivalent doses of other statins in both lowering LDL-C levels and in enabling patients to achieve NCEP ATP III LDL-C goals. 1016/S0002-9149(03)00530-7 Corpus ID: 88330662; Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial) Feb 13, 2024 · In particular, the STELLAR study showed that it was the most powerful statin, since, after 6 weeks of treatment, rosuvastatin 10–40 mg was able to reduce LDL-C by 46–55%, compared to 37–51% with atorvastatin 10–80 mg, 28–39% with simvastatin 10–40 mg, and 20–30% with pravastatin 10–40 mg. 0 mmo l/L was ac h ieve dby 79% to 92% in rosuvas- tatin groups compare d wit h 52% to 81% in atorvastatin Sep 1, 2004 · DOI: 10. 1 Mar 4, 2023 · Administration of statins to lower elevated levels of low-density lipoprotein (LDL) cholesterol is the cornerstone of contemporary therapy to reduce the risk of major adverse cardiovascular events The goal of this study was to examine prospectively the effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin across dose ranges on non-HDL-C, apo B, apo A-I, and total cholesterol (TC):HDL-C, low-density lipoprotein cholesterol (LDL-C):HDL-C, non-HDL-C:HDL-C, and apo B:apo A-I ratios in patients with hypercholesterolemia (LDL-C >-160 mg/dL and <250 mg/dL and triglycerides <400 Statins lead to removal of VLDL and LDL from plasma, leading to reduction in particle number. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). undertreated. 3 mmol/L and <1. Sep 1, 2004 · The goal of this study was to examine prospectively the effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin across dose ranges on non-HDL-C, apo B, apo A-I, and total cholesterol (TC):HDL-C, low-density lipoprotein cholesterol (LDL-C):HDL-C, non-HDL-C:HDL-C, and apo B:apo A-I ratios in patients with hypercholesterolemia (LDL-C >-160 mg/dL and <250 mg/dL and triglycerides <400 the STELLAR (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin) study, compared rosuvastatin, atorvastatin, simvastatin and pravastatin across licensed doses for reducing LDL cholesterol and other lipid parameters in patients (n=2,431) with hypercholesterolaemia (LDL-C > 160 and < 250 mg/dL [> 4. 23–25 The STELLAR trial also revealed that statins are effective at lowering non-HDL-C20 by all the mechanisms noted. 3%, respectively. 1–6 In aggregate, use of statin therapy in these trials has been associated with an approximate 30% Mar 7, 2023 · Statins have different effects on various cholesterol and cholesterol-related molecules: Lowers LDL cholesterol levels: LDL is the “bad” type of cholesterol and is most closely linked to ASCVD. 6a 6b 6c McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group Rosuvastatin is a new statin with a high efficacy in reducing LDL cholesterol levels with a good safety profile. Non-HDL-C, a simple calculation (TC−HDL-C), may be a more accurate Rosuvastatin is Cost-Effective in Treating Patients to Low-Density Lipoprotein-Cholesterol Goals Compared with Atorvastatin, Pravastatin and Simvastatin: Analysis of the Stellar Trial Mark Hirsch , BSc [email protected] , John C. 006 Corpus ID: 19954130; Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. PubMed ID: 15904635 . The study found that rosuvastatin produced greater reductions in LDL-C compared to equivalent and higher doses of other statins. Dec 1, 2011 · Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Nicholls SJ, et al. Funding organisations are being misinformed if they consider the swapping of effective treatment in this high-risk population is at all benign. The STELLAR study29 was a 6-week, open-label, randomized, multicenter trial comparing rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of LDL cholesterol, changes in other lipid parameters, and achievement of NCEP-ATP III LDL-cholesterol goals. Aug 19, 2019 · The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and other studies reported an increased risk of developing diabetes mellitus in patients on statin therapy . 0. 001) compared with those of simvastatin and pravastatin . The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low This randomized clinical trial compares the efficacy of a treat-to-target low-density lipoprotein cholesterol (LDL-C) strategy of 50 to 70 mg/dL as the goal vs high-intensity statin therapy for the 3-year composite of death, myocardial infarction, stroke, or coronary revascularization in patients Apr 22, 2017 · The STELLAR trial was based on dose-to-dose comparisons between atorvastatin and rosuvastatin efficacy in reducing LDL-C. 4 HMG CoA inhibitors TABLE 2 Mean (SD) Baseline (BL) and Least-squares Mean Percentage Change from Baseline in LDL Cholesterol - "Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). other statins in lowering LDL cholesterol levels and enabling patients to achieve National Cholesterol Edu-cation Program Adult Treatment Panel III (NCEP ATP III) LDL cholesterol goals. Feb 4, 2006 · The STELLAR trial showed similar capabilities when comparing LDL lowering with rosuvastatin, atorvastatin, simvastatin, and pravastatin (Jones et al 2003). Am J Cardiol 2003;92:152–160. Smaller denser particles appear to be preferentially removed. Most insurance plans cover the generic forms of Crestor and Lipitor, with SingleCare coupons available to reduce out-of-pocket costs significantly. The STELLAR study was a 6-week randomized open-label trial that compared the efficacy of rosuvastatin, atorvastatin, simvastatin, and pravastatin in 2268 adults with primary hypercholesterolemia. However, healthcare providers and Feb 1, 2005 · A retrospective pharmacoeconomic analysis was performed using data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial. Methods: As part of the STELLAR trial, 1,146 women with elevated low-density lipoprotein cholesterol (LDL-C Statin intensity was defined according to low-density lipoprotein (LDL) reduction rate based on the VOYAGER and STELLAR trials. CLINTHERA. At present data about efficacy on mortality and morbidity of this statin are not available; but a very large program of clinical trials, named GALAXY, with over 20,000 subjects in 30 countries, is ongoing. The STELLAR Trial,2,3 which examines the comparative dose efficacy of rosuvastatin versus comparator statins, was the largest trial of its kind to date and should aid doctors in making informed therapeutic choices in the treatment of dyslipidaemia. Objective: The goal of this study was to examine prospectively the effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin across dose ranges on non-HDL-C, apo B, apo A-I, and total cholesterol (TC):HDL-C, low-density lipoprotein cholesterol (LDL-C):HDL-C, non-HDL-C:HDL-C, and apo B:apo A-I ratios in patients with week) 1~-16 and long-term (52-week) trials, lr,ls In the largest comparative statin study of its kind conducted to date, the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, rosuvastatin was compared with atorvastatin, Nov 20, 2008 · The trial was stopped after a median follow-up of 1. Jun 21, 2018 · ORION-4 is a randomised controlled trial testing a new medicine called inclisiran. 0 placebo control, p = 0. Drug costs were based on wholesale acquisition costs. Lipophilic statins are reported to increase the risk of elevated serum glucose levels, especially with higher doses. Adapted from the STELLAR trial. Study characteristics. Circulation. Methods: As part of the STELLAR trial, 1,146 women with elevated low-density lipoprotein cholesterol (LDL-C However, healthcare providers and authorities require information on its cost-effectiveness in the treatment of dyslipidaemia. This study compared the efficacy and safety of low doses of rosuvastatin (10 mg) and atorvastatin (20 mg) in high-risk patients with hypercholesterolemia. 1 Any relevant practitioner, including nurse practitioners and pharmacist prescribers, can apply for a Special Authority. 3 mmol/l), and achieved both ATP III LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) goals. Following a 6-week dietary lead-in period, hypercholesterolemic were randomized to 1 of 5 arms: CRESTOR 20 mg, atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, or simvastatin 40 mg once daily (period 1: 8 weeks). The primary end point was percentage change from baseline in LDL-C at Week 6. 9, 2004 Effects of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin on Non-High-Density Lipoprotein Cholesterol, Apolipoproteins, and Lipid Ratios in Patients with Hypercholesterolemia: Additional Results from the STELLAR Trial Peter H. Jul 6, 2012 · This is especially true in the present study since the STELLAR trial reported biomarker changes for each of the statin doses considered. In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor*) was compared Jan 1, 2003 · SUMMARY In the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial, the efficacy of rosuvastatin calcium (Crestor*) was compared with that of atorvastatin (Lipitor †), simvastatin (Zocor‡), and pravastatin (Pravachol§) for lowering plasma low-density lipoprotein cholesterol (LDL-C) after 6 weeks The new england journal of medicine 2196 n engl j med 359;21 www. " Dec 5, 2018 · The STELLAR trial found Crestor slightly more effective than Lipitor in lowering LDL cholesterol and increasing HDL cholesterol, though both drugs effectively achieve cholesterol goals. The study has recruited 16,124 participants in the UK and USA. 6,9 Thus, identifying the optimal statin therapy and dose titration strategy to improve drug adherence and to achieve a sufficient reduction in LDL-C level is crucial. 3 During follow-up, we titrated statin intensity based on the obtained LDL cholesterol levels: up-titration for those whose LDL cholesterol levels were ≥1. nejm. Setting 12 hospitals in South Korea, September 2016 to November 2019. Apr 2, 2009 · Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. 8 mmol/L). FIGURE 3. The meta-analysis Insights on Statin Therapy & LDL Cholesterol from the CLEAR Outcomes Trial tein (LDL) cholesterol and achieving LDL cholesterol goalsthan atorvastatin, simvastatin, or pravastatin. arna aubkpd hpf xmvz cuaut ducsav qrfvjt zmrf gfbgadx fqtkh